NCT07410377WithdrawnEarly phase 1
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
A Clinical Study Evaluating the Safety and Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells（QT-019C） in With Relapse/Refractory Autoimmune Diseases.
- Status (registry)
- Withdrawn
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- First submitted
- 8 Feb 2026
- Start date
- Mar 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Diseases
- Lupus (SLE)
- NCT number
- NCT07410377
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1. Participants with a history of severe drug allergies or allergic constitutions.2. Presence or suspicion of uncontrolled or treatment-required fungal, bacterial, viral, or other infections.3. Participants with insufficient cardiac function.4. Participants with congenital immunoglobulin deficiencies.5. History of malignancy within five years.
Who the study is looking for
- 1. Age ≥ 18 years old (inclusive), regardless of gender. 2. Adequate hepatic, renal and bone marrow function.3 Participants with relapsed or refractory autoimmune diseases, Including SLE or IM.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The affiliated hospital of xuzhou medical university | Xuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.